41 results
Page 2 of 3
8-K
EX-99.2
57orsdwt7p5co0np s8x
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.2
sfs9v
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
p0oqhdo
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
tsoqui1 8k2k52
2 Mar 21
Regulation FD Disclosure
8:00am
8-K
EX-99.1
7j3g5dkk2h0cm0
4 Jan 21
Aravive Announces Board Member Transition to Advisory Role
4:11pm
8-K
EX-99.2
sda1xzm8xuzse 7hb7
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
msfy3
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
1oys2fzxxpo
5 Nov 20
Aravive Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
4:31pm
8-K
EX-99.1
t11x7y385oz0bu
3 Aug 20
Aravive Reports Second Quarter 2020 Financial Results and Provides Recent Corporate Updates
4:10pm
8-K
EX-99.1
9nctc7qlu55rk z3l
23 Jul 20
Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500
7:05am
S-4
kqpc35io
3 Aug 18
Registration of securities issued in business combination transactions
5:26pm
10-K
gludxmrf4xxpivi
6 Mar 15
Annual report
12:00am
424B4
7l6l8l xvkd
22 Jan 15
Prospectus supplement with pricing info
12:00am
424B4
chokryp6a 9j
21 Mar 14
Prospectus supplement with pricing info
12:00am